全文获取类型
收费全文 | 8745篇 |
免费 | 530篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 126篇 |
儿科学 | 276篇 |
妇产科学 | 263篇 |
基础医学 | 905篇 |
口腔科学 | 139篇 |
临床医学 | 786篇 |
内科学 | 2285篇 |
皮肤病学 | 82篇 |
神经病学 | 911篇 |
特种医学 | 338篇 |
外科学 | 941篇 |
综合类 | 93篇 |
一般理论 | 6篇 |
预防医学 | 988篇 |
眼科学 | 158篇 |
药学 | 570篇 |
中国医学 | 2篇 |
肿瘤学 | 432篇 |
出版年
2024年 | 7篇 |
2023年 | 35篇 |
2022年 | 59篇 |
2021年 | 178篇 |
2020年 | 83篇 |
2019年 | 169篇 |
2018年 | 194篇 |
2017年 | 163篇 |
2016年 | 147篇 |
2015年 | 172篇 |
2014年 | 281篇 |
2013年 | 391篇 |
2012年 | 633篇 |
2011年 | 695篇 |
2010年 | 383篇 |
2009年 | 376篇 |
2008年 | 575篇 |
2007年 | 691篇 |
2006年 | 649篇 |
2005年 | 616篇 |
2004年 | 584篇 |
2003年 | 540篇 |
2002年 | 475篇 |
2001年 | 106篇 |
2000年 | 71篇 |
1999年 | 81篇 |
1998年 | 106篇 |
1997年 | 80篇 |
1996年 | 63篇 |
1995年 | 71篇 |
1994年 | 49篇 |
1993年 | 50篇 |
1992年 | 61篇 |
1991年 | 38篇 |
1990年 | 45篇 |
1989年 | 67篇 |
1988年 | 40篇 |
1987年 | 28篇 |
1986年 | 28篇 |
1985年 | 19篇 |
1984年 | 34篇 |
1983年 | 21篇 |
1982年 | 26篇 |
1981年 | 25篇 |
1980年 | 18篇 |
1979年 | 11篇 |
1978年 | 14篇 |
1977年 | 11篇 |
1976年 | 9篇 |
1971年 | 6篇 |
排序方式: 共有9301条查询结果,搜索用时 15 毫秒
151.
Roy P Bonello L de Labriolle A Okabe T Pinto Slottow TL Steinberg DH Torguson R Smith K Xue Z Satler LF Kent KM Suddath WO Pichard AD Waksman R 《The American journal of cardiology》2008,102(3):292-297
Multiple studies comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with coronary artery disease have been performed. Despite these comparisons, it remains uncertain whether a differential in long-term efficacy and safety exists. Unselected patients treated exclusively with 1 drug-eluting stent type were enrolled in the Registry Experience at the Washington Hospital Center with Drug-Eluting Stents. There were 2,099 patients (3,766 lesions) treated with SES and 1,079 patients (1,850 lesions) treated with PES. Patients were followed at 30 days, 1 year, and 2 years for the clinical endpoints of death, myocardial infarction, target vessel revascularization, and definite and definite/probable stent thrombosis. Patients in the SES group had more dyslipidemia, history of congestive heart failure, and ostial lesions; patients treated with PES had more previous coronary artery bypass surgery, unstable angina, and type C lesions. At 2 years, unadjusted major adverse cardiac events (MACE) (22.6% vs 21.1%, p = 0.3) and target vessel revascularization (13.3% vs 11.2%, p = 0.1) were comparable. The incidence of definite stent thrombosis was higher in the SES group (1.8% vs 0.9%, p = 0.05) driven by early events. Similar results were seen after adjustment for baseline differences: MACE (hazard ratio 1.1, 95% confidence interval [CI] 0.9 to 1.3, p = 0.5), definite stent thrombosis (hazard ratio 2.3, 95% CI 1.0 to 5.2, p = 0.05), and target vessel revascularization (hazard ratio 1.1, 95% CI 0.9 to 1.4, p = 0.4). The incidence and rate of late stent thrombosis (>30 days) were similar (0.7% vs 0.5%, p = 0.4 and 0.24%/year, both groups, respectively). In conclusion, no major differential in long-term safety or efficacy was detected between SES and PES; both stent types were efficacious in reducing revascularization but were limited by a small continual increase in late stent thrombosis. 相似文献
152.
Steinberg DH Shah P Kinnaird T Pinto Slottow TL Roy PK Okabe T Bonello L de Labriolle A Smith KA Torguson R Xue Z Suddath WO Kent KM Satler LF Pichard AD Lindsay J Waksman R 《The American journal of cardiology》2008,102(2):160-164
For patients undergoing elective percutaneous coronary intervention (PCI), procedural anticoagulation with bivalirudin was previously shown to significantly reduce bleeding complications at the cost of a modest increase in ischemic events compared with unfractionated heparin (UFH) and glycoprotein IIb/IIIa inhibitors (GPIs). However, the excess bleeding in patients treated with UFH and GPIs may have been caused by excessively high UFH doses and increased activated clotting times. This study sought to determine the bleeding risk of targeted low-dose UFH with GPIs compared with bivalirudin in patients undergoing elective PCI. Of 1,205 patients undergoing elective PCI, 602 underwent PCI with adjunctive UFH and GPIs with the UFH dose targeted to an activated clotting time of approximately 250 seconds, and 603 patients matched for baseline characteristics underwent PCI with bivalirudin. Outcomes were analyzed for major bleeding (hematocrit decrease >15%, gastrointestinal bleed, or major hematoma) and 6-month major adverse cardiac events (death, myocardial infarction, and target-lesion revascularization). The maximum activated clotting time achieved was 261.7 +/- 61.6 seconds in the UFH/GPI group and 355.4 +/- 66.6 in the bivalirudin group (p <0.001). In-hospital major bleeding rates were similar between groups (1.8% UFH/GPI vs 1.7% bivalirudin; p = 0.83), as were transfusion requirements (1.2% UFH/GPI vs 0.5% bivalirudin; p = 0.61). The 6-month major adverse cardiac event rate was also similar between groups (9.5% UFH/GPI vs 9.0% bivalirudin; p = 0.81). In conclusion, there were no significant differences in major bleeding and 6-month major adverse cardiac events for patients undergoing elective PCI treated with targeted low-dose UFH and GPIs compared with those treated with bivalirudin. 相似文献
153.
Edouard Cheneau Daniel Canos Ellen Pinnow Andrew E Ajani Lowell F Satler Augusto D Pichard Kenneth M Kent Joseph Lindsay Ron Waksman 《Catheterization and cardiovascular interventions》2004,62(3):318-322
To determine the safety and efficacy, including the impact, on the late recurrence rate of an incremental gamma-radiation dose from 15 to 18 Gy, we report the 3-year clinical outcome of Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST). One hundred eighty patients with recurrent in-stent restenosis (ISR) were enrolled in the Long WRIST series and treated with (192)Ir with 1 month of antiplatelet therapy. Between 6 months and 3 years, the need for repeat revascularization was low and similar among the three groups. At 3 years, target lesion revascularization (TLR) and major adverse cardiac events (MACE) were less frequent in the 18 Gy group than in the 15 Gy group (P = 0.12 for TLR, P < 0.05 for MACE) and less frequent in the 15 Gy group as compared to the placebo group (P < 0.05 for TLR and MACE). At 3 years, a higher dose of 18 Gy with (192)Ir continues to improve the outcome of patients treated for ISR when compared to patients treated with 15 Gy or placebo. 相似文献
154.
Voronov E Shouval DS Krelin Y Cagnano E Benharroch D Iwakura Y Dinarello CA Apte RN 《Proceedings of the National Academy of Sciences of the United States of America》2003,100(5):2645-2650
Here, we describe that microenvironmental IL-1 beta and, to a lesser extent, IL-1 alpha are required for in vivo angiogenesis and invasiveness of different tumor cells. In IL-1 beta knockout (KO) mice, local tumor or lung metastases of B16 melanoma cells were not observed compared with WT mice. Angiogenesis was assessed by the recruitment of blood vessel networks into Matrigel plugs containing B16 melanoma cells; vascularization of the plugs was present in WT mice, but was absent in IL-1 beta KO mice. The addition of exogenous IL-1 into B16-containing Matrigel plugs in IL-1 beta KO mice partially restored the angiogenic response. Moreover, the incorporation of IL-1 receptor antagonist to B16-containing plugs in WT mice inhibited the ingrowth of blood vessel networks into Matrigel plugs. In IL-1 alpha KO mice, local tumor development and induction of an angiogenic response in Matrigel plugs was less pronounced than in WT mice, but significantly higher than in IL-1 beta KO mice. These effects of host-derived IL-1 alpha and IL-1 beta were not restricted to the melanoma model, but were also observed in DA/3 mammary and prostate cancer cell models. In addition to the in vivo findings, IL-1 contributed to the production of vascular endothelial cell growth factor and tumor necrosis factor in cocultures of peritoneal macrophages and tumor cells. Host-derived IL-1 seems to control tumor angiogenesis and invasiveness. Furthermore, the anti-angiogenic effects of IL-1 receptor antagonist, shown here, suggest a possible therapeutic role in cancer, in addition to its current use in rheumatoid arthritis. 相似文献
155.
Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients 总被引:6,自引:0,他引:6
Regar E Lemos PA Saia F Degertekin M Tanabe K Lee CH Arampatzis CA Hoye A Sianos G de Feyter P van der Giessen WJ Smits PC van Domburg RT Serruys PW 《The American journal of cardiology》2004,93(10):1271-1275
Sirolimus-eluting stents have been used in our institution for all percutaneous interventions, without clinical or anatomic exclusion criteria, as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital registry. We analyzed the incidence of (sub)acute stent thrombosis after sirolimus-eluting stent implantation in an unselected population of 510 consecutive patients. At 3-month follow-up, (sub)acute stent thrombosis was diagnosed in 2 patients (0.4%) 6 hours and 11 days after the procedure, respectively. These cases occurred in diabetic women with complex coronary lesions. Intravascular ultrasound examination showed inadequate stent expansion and uncovered distal dissection as possible mechanical explanations for the thrombosis. 相似文献
156.
Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction 总被引:12,自引:0,他引:12
157.
158.
Locating Ath8, a locus for murine atherosclerosis susceptibility and testing several of its candidate genes in mice and humans 总被引:3,自引:0,他引:3
Korstanje R Eriksson P Samnegård A Olsson PG Forsman-Semb K Sen S Churchill GA Rollins J Harris S Hamsten A Paigen B 《Atherosclerosis》2004,177(2):443-450
A previous study revealed that the difference in susceptibility to atherosclerotic lesions between inbred mouse strains SM/J and NZB/BlNJ was determined by one major locus (Ath8). In this study a (SM/J x NZB/BlNJ) F(1) x SM/J backcross localized Ath8 by quantitative trait locus mapping to chromosome 4 with a suggestive LOD score of 2.7. This quantitative trait locus (QTL) was confirmed using an (SM/J x NZB/BlNJ) intercross; Ath8 mapped to a 23cM region with a significant LOD score of 3.6. The genes for toll-like receptor 4 (T1r4), arachidonic acid epoxygenase (Cyp2j5), and angiopoietin-like protein 3 (Angptl3) map to this region. These candidate genes were analyzed for expression and sequence differences in the mouse and for associations with cardiovascular traits in human. Sequence analysis of Angptl3 shows a base pair substitution in SM, the susceptible strain, giving rise to an amino acid change in the fibrinogen homology domain of the protein. We found a significant association between ANGPTL3 and atherosclerotic lesions (P < 0.05) in human. These results suggest that Angptl3 is involved in atherosclerosis susceptibility in both mouse and human. 相似文献
159.
Davis MA Landesman R Tadmor B Hopmeier M Shenhar G Barker T Pozner CN Binstadt ES Nelson S Look R Shubina M Walls RM 《Annals of emergency medicine》2008,51(4):420-5, 425.e1-5
160.
Fernie J A Penning-van Beest Fabian Termorshuizen Wim G Goettsch Olaf H Klungel John J P Kastelein Ron M C Herings 《European heart journal》2007,28(2):154-159
AIMS: To investigate the 'real world' effectiveness of robust statin therapy, focusing on the effect of dose and early treatment discontinuation on the risk of hospitalization for acute myocardial infarction (AMI). METHODS AND RESULTS: In the PHARMO database, including among others drug-dispensing and hospital discharge records for more than two million subjects in the Netherlands, 59,094 new users of statins in the period 1 January 1991 until 31 December 2004, >or=18 years of age were identified. In these patients, exposure to statins, both in terms of persistence and dose, was determined over the first two treatment years. To determine the risk for AMI, patients were followed from this 2-year time point until the first hospital admission for AMI, death, or end of the study period. A total of 31,557 patients (53%) discontinued statin use within 2 years; 20 883 patients (35%) were persistent users with an average equipotent dose>or=4. A 30% reduction in risk of hospitalization for AMI with persistent statin use was observed. The protective effect increased with a higher dose (20 and 40% risk reduction with an equipotent doseor=4, respectively). CONCLUSION: These results show that statins are suboptimally used in real life for having the maximum benefit in terms of preventing AMI. 相似文献